Thomas Bridges

Displaying 1 - 1 of 1

Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.  

Related Categories: 
Aaron Bender Allison Gregro Basic Sciences biomedical research Carrie Jones clinical trial Colleen Niswender Craig Lindsley Darren Engers Discovery Vanderbilt Research Press release Food and Drug Administration Jeffrey Conn Jerri Rook Julie Engers Kayla Temple neuroscience Olivier Boutaud Pharmacology schizophrenia School of Medicine Basic Sciences Thomas Bridges Warren Center for Neuroscience Drug Discovery